Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157182" target="_blank" >RIV/00098892:_____/22:10157182 - isvavai.cz</a>

Alternative codes found

RIV/46747885:24530/22:00010464 RIV/00209805:_____/22:00078499 RIV/00216208:11110/22:10448712 RIV/00216224:14110/22:00128267 and 4 more

Result on the web

<a href="https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.055" target="_blank" >10.5507/bp.2020.055</a>

Result language

angličtina

Original language name

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

Original language description

Aim: The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and methods: Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. Results: 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. Conclusion: The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

1804-7521

Volume of the periodical

166

Issue of the periodical within the volume

1

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

97-104

UT code for WoS article

000731338900001

EID of the result in the Scopus database

2-s2.0-85122529005